ARTICLE | Clinical News
AGI-1096: AGIX began a U.S. Phase I trial of AGI-1096 in 48 healthy volunteers.
March 11, 2002 8:00 AM UTC
AtheroGenics Inc. (AGIX), Atlanta, Ga. Product: AGI-1096 Business: Transplant, Autoimmune/Inflammation Therapeutic category: Immune suppression Target: Inflammatory proteins including VCAM-1 Descript...